CUTR News and Press, Cutera Inc. From 05/02/22

CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that clinical data related to AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne; was presented during the...

Cutera, Inc. (Nasdaq: CUTR ) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2022 after the market close on Tuesday, May 10, 2022. T...

Cutera (NASDAQ:CUTR) and Synchrony (NYSE:SYF) entered an exclusive partnership to expand patient financing options to dermatology practices in the U.S. The companies said that dermatologists offering AviClear, Cutera’s device to treat acne, will have the option to accept...

Synchrony’s CareCredit enables flexible financing solutions for patients at dermatology practices in the CareCredit network offering Cutera’s AviClear™ laser acne treatment Exclusive partnership aims to help the millions who suffer with acne gain a...

AviClear uses proprietary technology to deliver safe and effective acne laser treatments with no need for adjunctive pain therapy Avi360 ™ partnership offers a suite of tools and services for easy integration into dermatology practices CUTERA, INC. (Na...

Cutera has had a great start to 2022, with shares up >50% on string FY21 results, FY22 guidance and approval for its acne therapy AviClear. The medical aesthetics company saw its share price devastated by the pandemic - the sector was particularly hard hit - but recovered rapidly. ...

The optimism on Wall Street continued during Tuesday's session, as the Nasdaq led the major U.S. equity indices higher yet again. As a result, the S&P 500 recorded its first close above 4,600 since mid-January. While the overall market pushed higher, in part on hopeful signs out of peace ...

Cutera (CUTR +9.7%) shares jump after Stifel analyst Jonathan Block raised the firm's price target to $70 from $60 and maintains a Buy rating on the shares as he believes that the company will pursue an upfront capital-light model for AviClear in exchange for an annual licensing fee, service ...

Gainers: Clever Leaves (CLVR) +28%. Tilray Brands (TLRY) +13%. Cutera (CUTR) +11%. STRATA Skin Sciences (SSKN) +10%. Clarus Therapeutics (CRXT) +8%. Losers: MEI Pharma (MEIP) -58%. Icosavax (ICVX) -50%. Rezolute (RZLT) -9%. Alpha Tau Medical (...

Cutera (NASDAQ:CUTR) said the U.S. Food and Drug Administration granted 510(k) clearance to AviClear to treat mild, moderate and severe Acne. The company said AviClear is the first and only energy-based device to receive this designation for treating mild, moderate, and severe acne....